News brief­ing: FDA lifts a hold on Po­sei­da study; Deci­bel adopts 2-AAV ap­proach to hear­ing loss; As­traZeneca part­ners on com­bos, again

A lit­tle more than 2 months ago, shares of new­ly pub­lic Po­sei­da Ther­a­peu­tics $PSTX cratered af­ter the biotech re­port­ed that a pa­tient death had spurred the FDA to drop a full hold on its lead can­cer drug. This morn­ing we learned that reg­u­la­tors lift­ed the hold, but de­tails are sparse.

In a state­ment out ear­ly Mon­day, Po­sei­da said that reg­u­la­tors had lift­ed the hold on their Phase I study for their CAR-T P-PS­MA-101 in prostate can­cer. Here’s why:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER